MnTBAP attenuates pulmonary hypertension-induced right ventricular dysfunction and remodeling by modulating the CaMKIIδ-SERCA2a signaling pathway - PubMed
5 hours ago
- #pulmonary hypertension
- #CaMKIIδ-SERCA2a pathway
- #right ventricular dysfunction
- MnTBAP is a synthetic manganese-based superoxide dismutase (SOD) mimetic with anti-inflammatory and antioxidant properties.
- MnTBAP attenuates pulmonary arterial hypertension (PAH) and prevents right ventricular (RV) hypertrophy, fibrosis, and oxidative stress in rats.
- The therapeutic effects of MnTBAP are achieved by suppressing aberrant CaMKIIδ phosphorylation in the myocardium.
- MnTBAP downregulates calcineurin A and sodium-calcium exchanger type 1 (NCX1) while restoring phospholamban (PLN) phosphorylation.
- MnTBAP reconstructs the expression of SERCA2a, effectively alleviating monocrotaline (MCT)-induced right heart failure (RHF).
- The study suggests MnTBAP as a potential therapeutic candidate for PAH-associated RHF.